RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg talks to Proactive London's Katie Pilbeam about their 2020 financial results and operational highlights.
Goldberg explains how 2020 was a 'pivotal year for the company that transformed RedHill and sets us up for success in 2021 both on the commercial and R&D side'.
He says despite the challenges of the year, they delivered 'consistent growth' and the plan for commercial operational breakeven is still targeted for the end of 2021.
Talicia has had consistent month-over-month prescription growth despite pandemic conditions, with 52% new prescription growth in Q4/2020 compared to Q3/2020. Movantik has maintained its market leadership position. Meanwhile on the R&D side, their two advanced COVID-19 programs (opaganib and RHB-107) are at the forefront of global novel therapeutics development.
Disclaimer: This content has been provided pursuant to an agreement under which RedHill Biopharma pays an annual fee to the publisher.